what defines the value of cryptocurrency, Knowledge

Nine associations, including China Consumers Association and internet society of china, China Hotel Association, China Self-employed Workers Association, china electronic chamber of commerce, China Packaging Federation, China Chain Store & Franchise Association, China Baked Food and Sugar Products Industry Association and China Nutrition Society, jointly proposed on December 11 to encourage catering industry operators (including self-employed workers) to curb catering waste in the industry through innovative measures, public welfare publicity and optimized services.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Trump said that individuals or companies that invest more than $1 billion in the United States will get accelerated approval. US President-elect Trump wrote in a post on his social media Truth Social on Tuesday: "Any individual or company that invests more than $1 billion in the United States will get comprehensive and accelerated approval and permission, including but not limited to all environmental approvals." This is the latest sign that Trump intends to relax the supervision of federal agencies and attract more foreign investment during his second term.

In November, the scale of wealth management exceeded expectations, and the scale of 14 wealth management companies increased by over 420 billion yuan. In November, the product scale of wealth management companies ushered in a general increase. According to the obtained data, in November, there were 6 state-owned wealth management companies and 8 joint-stock wealth management companies (CMB, Xingyin, Everbright, Xinyin, Ping 'an, Huaxia, Puyin and Minsheng), totaling 14 wealth management companies, with a survival scale of nearly 22.6 trillion yuan, an increase of more than 420 billion yuan compared with October, and the growth rate was slightly lower than the impact of capital backflow in October. (21st century business herald)After the strike ended, the delivery of Boeing aircraft dropped to 13 in November. On Tuesday, Boeing reported that it delivered 13 commercial jets in November, less than a quarter of the 56 jets delivered to customers 12 months ago. The number of deliveries in October decreased from 14 in October, when most of the company's aircraft production was still in a state of suspension, and 33,000 factory workers went on strike for seven weeks, which ended on November 5. Boeing shares closed up 4.5% on Tuesday. The aircraft manufacturer said that after weeks of methodical preparations, the company restarted the production of the 737 MAX and loaded the new fuselage into the Renton factory in Seattle.Morgan Asset Management: In 2025, there are sufficient reasons to continue to over-allocate US stocks. Sylvia Sheng, global multi-asset strategist of Morgan Asset Management, said that there are sufficient reasons to continue to over-allocate US stocks and increase exposure to small and medium-sized stocks. She pointed out that although the valuation may look high, it is expected that the profit growth of S&P 500 companies will continue. Sheng wrote that it is estimated that in 2025, the contribution of the six giants in the S&P 500 index to the profit growth of the other 494 stocks will be the same, and the profit growth of these six giants is expected to slow down from 40% in 2024 to 22%. In the international market, Morgan Asset Management continues to over-allocate Japanese stocks, and its quantitative model shows that the yield of Japanese stocks is attractive and the bottom-up profitability is strong.

The second meeting of the Global Foreign Exchange Market Committee in 2024 was successfully held. From December 5 to December 6, 2024, the second meeting of the Global Foreign Exchange Committee (GFXC) in 2024 was held online. The meeting discussed the promotion and implementation of global standards, the second round of three-year review of global standards, the operation of foreign exchange market and related market hot issues. Representatives from China Foreign Exchange Market Steering Committee (CFXC) attended the meeting. This meeting discussed the final results of the second round of three-year review of global standards. The Working Group on Foreign Exchange Settlement Risk and the Working Group on Foreign Exchange Data respectively introduced the final revision suggestions of the relevant provisions of the global standards, and how the Working Group continuously improved according to the public comments and feedback from the local foreign exchange market committees and in October 2024. The revision of the Global Standards aims to strengthen the relevant principles of foreign exchange settlement risk management and enhance the transparency of specific types of foreign exchange transactions and the use of customer-generated data on electronic trading platforms. GFXC members strongly support this.Tang Shikai, a member of the board of directors of Mercedes-Benz, will retire next year and is now in charge of the company's business in Greater China. Mercedes-Benz Group Co., Ltd. announced that Hubertus Troska, the current member of the board of directors in charge of the company's business in Greater China, will retire in 2025 as planned. He himself decided to take up a new position as a member of the board of directors of Mercedes-Benz Group Co., Ltd. and a special representative for China affairs from February 1, 2025 to promote the company's business system in the world's largest market. Tang Shikai will officially retire on July 31, 2025.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.